PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1985 February; 78(2): 129–135.
PMCID: PMC1289584

Hormonal aspects of prostatic cancer: a review.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ahmed SR, Brooman PJ, Shalet SM, Howell A, Blacklock NJ, Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet. 1983 Aug 20;2(8347):415–419. [PubMed]
  • Allen JM, O'Shea JP, Mashiter K, Williams G, Bloom SR. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1607–1609. [PMC free article] [PubMed]
  • Allen JM, Kerle DJ, Ware H, Doble A, Williams G, Bloom SR. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. Br Med J (Clin Res Ed) 1983 Dec 10;287(6407):1766–1766. [PMC free article] [PubMed]
  • Baker HW, Burger HG, De Kretser DM, Hudson B, Straffon WG. Effects of synthetic oral oestrogens in normal men and patients with prostatic carcinoma: lack of gonadotrophin suppression by chlorotrianisene. Clin Endocrinol (Oxf) 1973 Oct;2(4):297–306. [PubMed]
  • Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978 Nov 10;202(4368):631–633. [PubMed]
  • Bergquist C, Nillius SJ, Bergh T, Skarin G, Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh) 1979 Aug;91(4):601–608. [PubMed]
  • Bergquist C, Nillius SJ, Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception. 1979 May;19(5):497–506. [PubMed]
  • Bhanalaph T, Varkarakis MJ, Murphy GP. Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg. 1974 Jan;179(1):17–23. [PubMed]
  • Biorn CL, Gray CP, Strauss E. Urology-epitomes of progress: orchiectomy after presumed estrogen failure in treatment of carcinoma of the prostate. West J Med. 1979 Apr;130(4):363–364. [PMC free article] [PubMed]
  • Blackard CE, Byar DP, Jordan WP., Jr Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology. 1973 Jun;1(6):553–560. [PubMed]
  • Bourne GA, Regiani S, Payne AH, Marshall JC. Testicular GnRH receptors--characterization and localization on interstitial tissue. J Clin Endocrinol Metab. 1980 Aug;51(2):407–409. [PubMed]
  • Boyns AR, Cole EN, Phillips ME, Hillier SG, Cameron EH, Griffiths K, Shahmanesh M, Feneley RC, Hartog M. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens. Eur J Cancer. 1974 Jul;10(7):445–449. [PubMed]
  • Brendler H. Adrenalectomy and hypophysectomy for prostatic cancer. Urology. 1973 Aug;2(2):99–102. [PubMed]
  • BUELL P, DUNN JE., Jr CANCER MORTALITY AMONG JAPANESE ISSEI AND NISEI OF CALIFORNIA. Cancer. 1965 May;18:656–664. [PubMed]
  • Byar DP. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med. 1972 Jun;48(5):751–766. [PubMed]
  • Catalona WJ, Scott WW. Carcinoma of the prostate: a review. J Urol. 1978 Jan;119(1):1–8. [PubMed]
  • Chaisiri N, Valotaire Y, Evans BA, Pierrepoint CG. Demonstration of a cytoplasmic receptor protein for oestrogen in the canine prostate gland. J Endocrinol. 1978 Jul;78(1):131–139. [PubMed]
  • Clark P, Houghton L. Subcapsular orchidectomy for carcinoma of the prostate. Br J Urol. 1977 Oct;49(5):419–425. [PubMed]
  • Coy DH, Schally AV. Gonadotrophin releasing hormone analogues. Ann Clin Res. 1978;10(3):139–144. [PubMed]
  • DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981 Jun;19(6):1073–1074. [PMC free article] [PubMed]
  • Ekman P, Snochowski M, Zetterberg A, Högberg B, Gustafsson JA. Steroid receptor content in human prostatic carcinoma and response to endocrine therapy. Cancer. 1979 Oct;44(4):1173–1181. [PubMed]
  • Franchimont P. Pituitary gonadotrophins. Clin Endocrinol Metab. 1977 Mar;6(1):101–116. [PubMed]
  • Geller J, Cantor T, Albert J. Evidence for a specific dihydrotestosterone-binding cytosol receptor in the human prostate. J Clin Endocrinol Metab. 1975 Nov;41(5):854–862. [PubMed]
  • Girard J, Baumann JB. Proceedings: Secondary adrenal insufficiency due to cyproterone acetate. J Endocrinol. 1976 Jun;69(3):13P–14P. [PubMed]
  • Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H. Tamoxifen in refractory metastatic carcinoma of the prostate. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):813–818. [PubMed]
  • Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer. 1982 Apr 1;49(7):1367–1372. [PubMed]
  • Hsueh AJ, Erickson GF. Extrapituitary action of gonadotropin-releasing hormone: direct inhibition ovarian steroidogenesis. Science. 1979 May 25;204(4395):854–855. [PubMed]
  • Huggins C, Scott WW. Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg. 1945 Dec;122(6):1031–1041. [PubMed]
  • Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol. 1982 Aug;128(2):335–340. [PubMed]
  • Monahan MW, Amoss MS, Anderson HA, Vale W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry. 1973 Nov 6;12(23):4616–4620. [PubMed]
  • NESBIT RM, BAUM WC. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J Am Med Assoc. 1950 Aug 12;143(15):1317–1320. [PubMed]
  • Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C, Stevens DA. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. [PubMed]
  • Prout GR, Jr, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967 Nov;20(11):1871–1878. [PubMed]
  • Redding TW, Coy DH, Schally AV. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1273–1276. [PubMed]
  • Resnick MI, Grayhack JT. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):141–161. [PubMed]
  • Reynoso G, Murphy GP. Adrenalectomy and hypophysectomy in advanced prostatic carcinoma. Cancer. 1972 Apr;29(4):941–945. [PubMed]
  • Sanford EJ, Drago JR, Rohner TJ, Jr, Santen R, Lipton A. Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. J Urol. 1976 Feb;115(2):170–174. [PubMed]
  • Schally AV, Nair RM, Carter WH. Countercurrent distribution as a tool for purification of hypothalamic hormones on a preparative scale. Anal Chem. 1971 Sep;43(11):1527–1529. [PubMed]
  • Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol. 1973 Dec;45(6):668–677. [PubMed]
  • Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970 Sep;49(9):1737–1745. [PMC free article] [PubMed]
  • Silverberg GD. Hypophysectomy in the treatment of disseminated prostate carcinoma. Cancer. 1977 Apr;39(4):1727–1731. [PubMed]
  • Sinha AA, Blackard CE, Doe RP, Seal US. The in vitro localization of H 3 estradiol in human prostatic carcinoma. An electron microscopic autoradiographic study. Cancer. 1973 Mar;31(3):682–688. [PubMed]
  • Spremulli E, DeSimone P, Durant J. A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am J Clin Oncol. 1982 Apr;5(2):149–153. [PubMed]
  • Stone AR, Hargreave TB, Chisholm GD. The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Urol. 1980 Dec;52(6):535–538. [PubMed]
  • Tharandt L, Schulte H, Benker G, Hackenberg K, Reinwein D. Treatment of isolated gonadotropin deficiency in men with synthetic LR-RH and a more potent analogue of LH-RH. Neuroendocrinology. 1977;24(3-4):195–207. [PubMed]
  • Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. [PubMed]
  • Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol. 1983 Jul;130(1):152–153. [PubMed]
  • Walker KJ, Nicholson RI, Turkes AO, Turkes A, Griffiths K, Robinson M, Crispin Z, Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet. 1983 Aug 20;2(8347):413–415. [PubMed]
  • Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. [PMC free article] [PubMed]
  • Worgul TJ, Santen RJ, Samojlik E, Veldhuis JD, Lipton A, Harvey HA, Drago JR, Rohner TJ. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol. 1983 Jan;129(1):51–55. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press